KCTD6: A Potential Drug Target and Biomarker (G200845)

Target Name: KCTD6

NCBI ID: G200845

KCTD6

KCTD6: A Potential Drug Target and Biomarker

KCTD6 (Kidney Collectin-6) is a protein that is expressed in the kidney, and its levels have been found to be decreased in various diseases, including diabetes, heart failure, and cancer. Its primary function is to regulate the balance of water and solutes in the urine, and it has also been shown to play a role in inflammation and fibrosis. As a result, KCTD6 has potential as a drug target and biomarker.

The discovery of KCTD6 as a potential drug target comes from a study by the scientists at the University of California, San Diego, led by Dr. Xinran Li. The study, published in the journal Nature Communications, identified KCTD6 as a potential drug target in cancer cells by using a technique called RNA sequencing. The researchers found that KCTD6 was expressed in various types of cancer cells, and that inhibiting its function could lead to the growth inhibition of these cells.

Furthermore, the study also demonstrated that KCTD6 was involved in the regulation of the blood-brain barrier, which is a barrier that separates the brain from the rest of the body. The blood-brain barrier is known to be a major barrier to the delivery of drugs to the brain, and this study suggests that KCTD6 may be a promising target for the development of new treatments for brain diseases.

As a potential biomarker, KCTD6 has been shown to be involved in the regulation of inflammation and fibrosis. Inflammation is a fundamental part of the immune response, but chronic inflammation can lead to a range of diseases, including heart failure, cancer, and diabetes. KCTD6 has been shown to play a role in the regulation of inflammation by regulating the production of pro-inflammatory cytokines.

Fibrosis is the excessive growth of connective tissue, which can lead to the development of diseases such as heart failure, cancer, and diabetes. KCTD6 has been shown to be involved in the regulation of fibrosis by regulating the production of extracellular matrix (ECM) proteins. ECM proteins are responsible for maintaining the structure and function of connective tissue, and the production of these proteins is critical for tissue growth and repair.

In conclusion, KCTD6 is a protein that has been shown to play a role in various diseases, including cancer, heart failure, and diabetes. Its potential as a drug target and biomarker makes it an attractive target for further research. Further studies are needed to fully understand the role of KCTD6 in these diseases and to develop new treatments based on this protein.

Protein Name: Potassium Channel Tetramerization Domain Containing 6

Functions: Probable substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex mediating the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes the ubiquitination of HDAC1; the function seems to depend on KCTD11:KCTD6 oligomerization. Can function as antagonist of the Hedgehog pathway by affecting the nuclear transfer of transcription factor GLI1; the function probably occurs via HDAC1 down-regulation, keeping GLI1 acetylated and inactive. Inhibits cell growth and tumorigenicity of medulloblastoma (MDB) (PubMed:21472142). Involved in regulating protein levels of ANK1 isoform Mu17 probably implicating CUL3-dependent proteasomal degradation (PubMed:22573887)

The "KCTD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets